News stories about Dimension Therapeutics (NASDAQ:DMTX) have trended somewhat positive recently, Accern reports. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Dimension Therapeutics earned a news impact score of 0.10 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 43.9284884946536 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

DMTX has been the topic of a number of recent analyst reports. ValuEngine upgraded shares of Dimension Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, September 30th. Wells Fargo & Company lowered shares of Dimension Therapeutics from an “outperform” rating to a “market perform” rating and cut their price target for the company from $9.00 to $6.00 in a research note on Tuesday, October 3rd. Citigroup Inc. upgraded shares of Dimension Therapeutics from a “sell” rating to a “neutral” rating and upped their price target for the company from $5.50 to $6.00 in a research note on Tuesday, October 3rd. Canaccord Genuity lowered shares of Dimension Therapeutics from a “buy” rating to a “hold” rating and cut their price target for the company from $12.00 to $3.41 in a research note on Wednesday, August 30th. Finally, Chardan Capital restated a “hold” rating on shares of Dimension Therapeutics in a research note on Monday, August 14th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $5.08.

Dimension Therapeutics (NASDAQ DMTX) opened at 5.975 on Wednesday. Dimension Therapeutics has a 52 week low of $1.05 and a 52 week high of $6.17. The firm’s market cap is $149.69 million. The firm’s 50-day moving average is $5.75 and its 200-day moving average is $2.64.

Dimension Therapeutics (NASDAQ:DMTX) last released its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.49) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.49). Dimension Therapeutics had a negative net margin of 358.21% and a negative return on equity of 98.72%. The company had revenue of $4.37 million for the quarter. On average, equities analysts anticipate that Dimension Therapeutics will post ($1.99) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This piece of content was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://theolympiareport.com/2017/11/01/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-dimension-therapeutics-dmtx-stock-price.html.

Dimension Therapeutics Company Profile

Dimension Therapeutics, Inc is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa).

Insider Buying and Selling by Quarter for Dimension Therapeutics (NASDAQ:DMTX)

Receive News & Ratings for Dimension Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dimension Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.